Caseware UK (AP4) 2023.0.135 2023.0.135 No description of principal activity02023-07-01falseThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.0falsetrue 10231985 2024-06-30 10231985 2023-07-01 2024-06-30 10231985 2022-07-01 2023-06-30 10231985 c:Director1 2023-07-01 2024-06-30 10231985 2023-06-30 10231985 c:Director2 2023-07-01 2024-06-30 10231985 d:CurrentFinancialInstruments 2024-06-30 10231985 d:CurrentFinancialInstruments 2023-06-30 10231985 d:CurrentFinancialInstruments d:WithinOneYear 2024-06-30 10231985 d:CurrentFinancialInstruments d:WithinOneYear 2023-06-30 10231985 d:ShareCapital 2024-06-30 10231985 d:ShareCapital 2023-06-30 10231985 d:RetainedEarningsAccumulatedLosses 2024-06-30 10231985 d:RetainedEarningsAccumulatedLosses 2023-06-30 10231985 c:FRS102 2023-07-01 2024-06-30 10231985 c:AuditExempt-NoAccountantsReport 2023-07-01 2024-06-30 10231985 c:FullAccounts 2023-07-01 2024-06-30 10231985 c:PrivateLimitedCompanyLtd 2023-07-01 2024-06-30 10231985 e:PoundSterling 2023-07-01 2024-06-30 iso4217:GBP xbrli:pure
Company registration number: 10231985











TASA MEDICAL LTD
UNAUDITED
FINANCIAL STATEMENTS
INFORMATION FOR FILING WITH THE REGISTRAR
For the Year Ended 30 June 2024

















Coveney Nicholls Limited
Chartered Accountants
The Old Wheel House
31/37 Church Street
Reigate
Surrey
UK
RH2 0AD

 
TASA MEDICAL LTD
Registered number:10231985

BALANCE SHEET
As at 30 June 2024

2024
2023
Note
£
£

  

Current assets
  

Cash at bank and in hand
  
142,774
161,912

  
142,774
161,912

Creditors: amounts falling due within one year
  
(12,116)
(12,419)

Net current assets
  
 
 
130,658
 
 
149,493

Total assets less current liabilities
  
130,658
149,493

  

Net assets
  
130,658
149,493


Capital and reserves
  

Called up share capital 
  
100
100

Profit and loss account
  
130,558
149,393

  
130,658
149,493


The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 29 January 2025.




___________________________
Dr TA Arain
___________________________
Mrs SR Arain
Director
Director

The notes on pages 2 to 5 form part of these financial statements.

Page 1

 
TASA MEDICAL LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS

For the Year Ended 30 June 2024

1.


General information

The company is a private company limited by shares, registered in England and Wales. The address of the registered office is The Old Wheel House, 31-37 Church Street, Reigate, Surrey, RH2 0AD, England.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

 
2.3

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

 
2.4

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.5

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.6

Financial instruments

Financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instruments any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities.

Basic financial liabilities, which include trade and other payables, bank loans and other loans are initially measured at their transaction price after transaction costs. When this constitutes a financing
Page 2

 
TASA MEDICAL LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS

For the Year Ended 30 June 2024

2.Accounting policies (continued)


2.6
Financial instruments (continued)

transaction, whereby the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest. Discounting is omitted where the effect of discounting is immaterial.

Debt instruments are subsequently carried at their amortised cost using the effective interest rate method.

Trade payables are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade payables are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade payables are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial.

 
2.7

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Creditors: Amounts falling due within one year

2024
2023
£
£

Corporation tax
-
2,367

Other taxation and social security
648
686

Other creditors
9,942
8,145

Accruals and deferred income
1,526
1,221

12,116
12,419



During the year the directors entered into the following advances and credits with the company:


2024

Balance brought forward and outstanding
Advances/(credits) to the directors
Amounts repaid
Balance outstanding

£
£
£
£

Dr TA Arain
4,072
(1,000)
1,899
4,971

Mrs SR Arain
4,072
(1,000)
1,899
4,971

2023
Page 3

 
TASA MEDICAL LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS

For the Year Ended 30 June 2024

Balance brought forward and outstanding
Advances/(credits) to the directors
Amounts repaid
Balance outstanding

£
£
£
£

Dr TA Arain
2,836
(2,000)
3,236
4,072

Mrs SR Arain
2,836
(2,000)
3,236
4,072

Page 4

 
TASA MEDICAL LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS

For the Year Ended 30 June 2024

4.


Related party transactions

The company was under the control of Dr TA Arain and Mrs SR Arain throughout the year. Dr and Mrs Arain are the only directors and are equal shareholders. During the year director expenses incurred via the business totalled £1,797 (2023 - £2,472). Dividends of £2,000 (2023 - £4,000) were paid to the directors in the year. At the balance sheet of 30th June 2024, £9,942 (2023 £8,144) was owed to the directors, which is made up of the above. No other transactions were undertaken which would require to be disclosed under FRS 102. 

 
Page 5